According to Reuters, the grocery retailer notified Express Scripts in September 2022 of its plan to terminate the pharmacy ...

ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

EST AbbVie (ABBV) seeing ‘significant advancements’ across entire pipelineInvest with Confidence: Follow TipRanks' Top Wall Street ...

Says therapeutic portfolio ‘demonstrating very strong momentum’ into 2025. Says making “significant progress” in R&D efforts. Invest with ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

As the company navigates the post-Humira era, investors and analysts are closely watching its performance and future prospects. According to InvestingPro data, AbbVie stands as a prominent player ...

AbbVie faces its share of headwinds like Humira biosimilar erosion, increasing competitive pressure on cancer drug Imbruvica and slow market growth trends for fillers in the United States and China.

AbbVie has demonstrated resilience in the face of significant challenges, particularly the loss of exclusivity (LOE) for its blockbuster drug Humira. The company's second-quarter 2024 results ...

AbbVie (NYSE:ABBV) will report Q4 2024 results next week and provide guidance for 2025. The company is handling the erosion of Humira quite well, but the trajectory of the decline in Humira's net ...